IMNN Imunon, Inc.
Company Analysis
Latest News
Imunon's second quarter 2026 loss of $0.54 per share beat estimates with $1.5M R&D spend
Imunon reported a narrower-than-expected net loss of $2.8 million for the second quarter of 2026, driven by disciplined R&D spending even as clinical...
Imunon Inc Q2 2026 Earnings Preview: What Analysts Expect on August 11, 2026
Analysts expect Imunon Inc to report a Q2 2026 loss per share of $0.94 on negligible revenue, with the current stock price of $1.15 trading significantly below...
Imunon Inc Q2 2026 Earnings Preview: What Analysts Expect on August 04, 2026
For the second quarter of 2026, analysts expect Imunon Inc to report zero revenue and a consensus loss per share of $0.94, while the stock currently trades at...
Imunon Appoints Josh Blacher as New Interim Chief Financial Officer
Imunon, Inc. announced the appointment of Josh Blacher as its new interim Chief Financial Officer, effective July 1, 2026. Mr. Blacher replaces Jeffrey Church,...
Imunon Secures Up to $10 Million in Financing via Preferred Stock and Notes
Imunon, Inc. has entered into a securities purchase agreement with Streeterville Capital, LLC, securing up to $10 million in financing. The transaction, which...
🔴 IMNN is trading 5.5% down today amid volatility in the thinly traded biotech
IMNN is trading 5.5% down at $2.17 with no fresh company-specific news or filings to explain the move. • The drop appears related to typical volatility in a...
🔴 IMNN is trading 5.5% down today with no clear company-specific catalyst
IMNN is trading 5.5% down at $2.17 today despite a lack of fresh company-specific news, regulatory filings, or clinical trial readouts to explain the move. •...